The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis Jing JinHua SunGengtao Liu Preclinical Studies 26 August 2006 Pages: 95 - 105
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line Alan PourpakRobert T. DorrSteven P. Stratton Preclinical Studies 06 October 2006 Pages: 107 - 114
The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells Tracy A. BrooksKieran L. O’LoughlinMaria R. Baer Preclinical Studies 28 October 2006 Pages: 115 - 122
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer S. J. DawsonM. MichaelJ. R. Zalcberg Phase I Studies 20 October 2006 Pages: 123 - 129
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors Luis H. CamachoJon OlsonMark G. Malkin Phase I Studies 20 October 2006 Pages: 131 - 138
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients Thomas W. FlaigDaniel L. GustafsonL. Michael Glodé Phase I Studies 01 November 2006 Pages: 139 - 146
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor Amin M. AlousiRamesh BoinpallyPatricia M. LoRusso Phase I Studies 11 November 2006 Pages: 147 - 154
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma Michael G. SmylieRalph WongJean-Francois Pouliot PHASE II STUDIES 07 September 2006 Pages: 155 - 159
Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules Harold J. BursteinBeth OvermoyerEric P. Winer Phase II Studies 13 September 2006 Pages: 161 - 164
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers Matthew G. FuryAndrew ZahalskyDavid G. Pfister Phase II Studies 16 September 2006 Pages: 165 - 172
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study Stefan von DeliusFlorian EckelChristian Lersch PHASE II STUDIES 13 September 2006 Pages: 173 - 180
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia Gonzalo Gomez-AbuinEric WinquistMalcolm J. Moore PHASE II STUDIES 16 September 2006 Pages: 181 - 185